Cartilage degeneration

Cartilage degeneration is a pathological process involving the progressive erosion and eventual loss of articular cartilage, the specialized connective tissue that provides a low-friction surface for joint movement (PMC 2728271). It is characterized by a metabolic imbalance in chondrocytes where the production of catabolic enzymes, specifically matrix metalloproteinase-13 (MMP-13) and aggrecanases (ADAMTS-4 and -5), exceeds the capacity for extracellular matrix repair (MDPI 14:1527, NIH 34832795). This enzymatic breakdown targets the primary structural components of cartilage, including type II collagen and aggrecan, and is exacerbated by inflammatory cytokines like IL-1β and mechanical stress (PubMed 21455581). While it is the primary focus of disease-modifying osteoarthritis drugs (DMOADs), "Cartilage degeneration" is a disease state or clinical phenotype rather than a single molecular target; therapeutic agents instead target specific molecular drivers such as Wnt signaling (e.g., Lorecivivint) or fibroblast growth factor receptors (e.g., Sprifermin) to arrest the process (Front. Pharmacol. 14:1152062).

Other names

Articular cartilage lossChondral degradationChondrolysisOsteoarthritis progressionDegenerative joint disease

Modification of joint structure by inhibiting catabolic enzymes (e.g., MMP-13 and ADAMTS-5), modulating regulatory signaling pathways (e.g., Wnt inhibition or FGF18 stimulation) to promote chondrogenesis, or neutralizing pro-inflammatory cytokines (e.g., IL-1β and TNF-α) that drive matrix breakdown.